Deletion of CBFB in a patient with acute myelomonocytic leukemia (AML M4Eo) and inversion 16

Cancer Genetics and Cytogenetics
Nicole EganPaul Cannell

Abstract

Acute myelomonocytic leukemia with bone marrow eosinophilia (AML M4Eo) is a subtype of AML with distinct morphological features. Inversion (16)(p13.1q22), t(16;16)(p13.1;q22), and del(16)(q22) are nonrandom abnormalities associated with AML M4Eo and a favorable prognosis, compared with the standard risk group for AML. Deletions of the proximal region of the MYH11 gene located at 16p13.1 have been detected in about 20% of patients with inv(16), with an undetermined effect on patient survival. We present the case of a patient with AML M4Eo and inversion 16 with a distal deletion of the CBFB gene at 16q22 detected with fluorescence in situ hybridization. To our knowledge, only one previous report of a similar deletion has appeared in the literature.

References


❮ Previous
Next ❯

Citations

May 19, 2009·Leukemia Research·Michele MagniAlessandro M Gianni
Nov 6, 2007·Cancer Genetics and Cytogenetics·Deborah V SpencerDenise I Quigley
Oct 11, 2005·Cancer Genetics and Cytogenetics·Johanna KellyMichael J Neat
Sep 2, 2010·The Korean journal of laboratory medicine·Minki KimYoon Hwan Chang

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.